Last reviewed · How we verify
TENIVAC
At a glance
| Generic name | TENIVAC |
|---|---|
| Also known as | Tetanus and Diphtheria Toxoids Adsorbed, Td |
| Sponsor | Rutgers, The State University of New Jersey |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- Immunosuppression and COVID-19 Boosters (PHASE3)
- Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (PHASE1)
- PFAS Exposure and Immune Response to Vaccination in Adults (PHASE4)
- Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma (PHASE1)
- Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TENIVAC CI brief — competitive landscape report
- TENIVAC updates RSS · CI watch RSS
- Rutgers, The State University of New Jersey portfolio CI